South Korean Researchers Identify SHP Protein as Key Regulator in Halting Degenerative Cartilage Breakdown in Osteoarthritis

KRIBB researchers identify the SHP protein as a vital shield against cartilage breakdown, offering a new gene-therapy path for treating osteoarthritis.

By: AXL Media

Published: Mar 24, 2026, 5:42 AM EDT

Source: Information for this report was sourced from National Research Council of Science & Technology

A New Biological Target for Degenerative Joint Disease

The search for a treatment that addresses the root cause of osteoarthritis has shifted toward a specific protective protein identified by researchers in South Korea. While current medical interventions largely focus on temporary pain management, a team from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and Chungnam National University Hospital has pinpointed SHP (NR0B2) as a critical factor in cartilage preservation. By analyzing tissues from both human patients and animal models, the researchers observed that SHP levels plummet as osteoarthritis progresses. This decline directly correlates with the accelerated destruction of the cartilage that normally cushions bones, suggesting that maintaining this protein is essential for joint health.

Mechanisms of Cartilage Erosion and Enzymatic Suppression

The study revealed that the primary function of the SHP protein is to act as a biological brake on destructive processes within the joint. Specifically, SHP suppresses the production of matrix-degrading enzymes known as MMP-3 and MMP-13, which are the primary agents responsible for eating away at cartilage tissue. According to Dr. Chul-Ho Lee, the study's lead investigator, this inhibition occurs at the signaling level through the regulation of the IKKβ/NF-κB pathway. When SHP is absent or depleted, these enzymes are left unchecked, leading to the rapid degradation of the joint structure and the onset of debilitating mobility issues.

Experimental Validation and Pain Alleviation

To confirm the protective properties of the protein, the research team conducted experiments on mice lacking the SHP factor. These subjects experienced significantly more severe pain and faster cartilage decay than their healthy counterparts. Conversely, when the team artificially restored SHP levels within the joints, they observed a marked improvement in joint function and a notable reduction in physical damage. This dual observation provides the first concrete evidence that the presence of SHP is not merely a side effect of healthy joints but a mandatory requirement for preventing the mechanical wear and tear associated with aging and injury.